INBS

$3.71

Pre-MarketAs of Mar 17, 8:00 PM UTC

Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

MT Newswires
Jan 2, 2026

Top Midday Decliners

Intelligent Bio Solutions (INBS) reported late Wednesday an agreement with two healthcare-focused in

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Dec 31, 2025

BC-Most Active Stocks

td class="col-issue">New Era Energy & Digital Inc.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Aug 17, 2025

Intelligent Bio Solutions Full Year 2025 Earnings: US$2.00 loss per share (vs US$6.38 loss in FY 2024)

NasdaqCM:INBS 1 Year Share Price vs Fair Value Explore Intelligent Bio Solutions's Fair Values from the Community and...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Benzinga
Aug 7, 2025

EXCLUSIVE: Intelligent Bio Expects Double Digit Topline Growth In Q4

Intelligent Bio Solutions Inc. (NASDAQ:INBS) reported preliminary fiscal fourth quarter revenue results and selected operational highlights on Thursday. Intelligent Bio Solutions is a medical technology company delivering intelligent, rapid, noninvasive testing solutions. “Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth,” said Harry Simeonidis, Pres

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Benzinga
Jul 23, 2025

EXCLUSIVE: Intelligent Bio Solutions' New Data Confirms Ability To Detect Trace Sweat Volumes At Ultra-Micro Level

Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Wednesday announced the collection of new data that further reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission. "We are planning to submit our findings to the FDA in August, along with the new data collected," said Peter Passaris, Vice President of Product Development. The company completed cybersecurity testing, including penetration testing and electromagnetic c

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.